GlassScriptPhysician profile
Larry Hubbs
NPI 1316032519
$7,498.18
in general payments reported to CMS, 2019-2025
35 companies · $1,631 in 2025
The $1,631 reported for 2025 was more than what 93% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,638 · 2022: $1,433 · 2023: $1,474 · 2024: $1,322 · 2025: $1,631.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,427.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,426.85 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $957.73 | 2021-2025 | |
| Novo Nordisk INC | $725.23 | 2021-2025 | Wegovy, Ozempic, Rybelsus |
| Astrazeneca Pharmaceuticals LP | $719.36 | 2021-2025 | Airsupra, Farxiga, Fasenra |
| Lilly USA, LLC | $623.98 | 2021-2025 | Mounjaro, Zepbound, Jardiance |
| Pfizer INC. | $621.98 | 2021-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $410.97 | 2021-2025 | Jardiance, Spiriva Respimat, Jascayd |
| Esperion Therapeutics, INC. | $293.19 | 2021-2024 | Nexletol |
| Sanofi-Aventis U.S. LLC | $272.64 | 2021-2025 | |
| Merck Sharp & Dohme LLC | $259.91 | 2021-2024 | Gardasil 9, Vaxelis, Vaxneuvance |
| Glaxosmithkline, LLC. | $257.03 | 2022-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Gilead Sciences, INC. | $248.42 | 2022-2025 | |
| Abbott Laboratories | $215.24 | 2021-2024 | Freestyle Libre 2, Freestyle Libre 3 |
| Otsuka America Pharmaceutical, INC. | $187.63 | 2023-2025 | Rexulti |
| Bayer Healthcare Pharmaceuticals INC. | $166.06 | 2023-2025 | |
| Biohaven Pharmaceutical Holding Company LTD. | $156.45 | 2022 |
Show all 35 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Antares Pharma, INC. | $149.62 | 2022 | |
| Exact Sciences Corporation | $143.18 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $123.20 | 2021-2024 | Trulance, Xifaxan |
| Astellas Pharma US INC | $121.20 | 2021-2024 | Veozah |
| Phathom Pharmaceuticals, INC. | $114.74 | 2024-2025 | Voquezna |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $114.43 | 2025 | Caplyta |
| Dexcom, INC. | $93.92 | 2024-2025 | Dexcom G6 Transmitter |
| Idorsia Pharmaceuticals US INC | $82.20 | 2022-2024 | Quviviq |
| Amgen INC. | $76.85 | 2021-2024 | Prolia, Evenity, Repatha |
| Dynavax Technologies Corporation | $50.77 | 2025 | Heplisav-B |
| Novartis Pharmaceuticals Corporation | $47.89 | 2023 | |
| Xeris Pharmaceuticals, INC. | $47.68 | 2025 | Gvoke Hypopen |
| E.R. Squibb & Sons, L.L.C. | $39.61 | 2021-2022 | |
| Kowa Pharmaceuticals America, INC. | $33.81 | 2021 | |
| Ardelyx, INC. | $30.34 | 2025 | Ibsrela |
| Evoke Pharma, INC. | $29.50 | 2023 | Gimoti |
| Axsome Therapeutics, INC. | $25.89 | 2025 | Auvelity |
| Lundbeck LLC | $24.96 | 2024 | Rexulti |
| Jazz Pharmaceuticals INC. | $19.44 | 2021 | |
| Biohaven Pharmaceuticals, INC. | $13.13 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Larry Hubbs listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.